AR079970A1 - Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas - Google Patents

Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas

Info

Publication number
AR079970A1
AR079970A1 ARP110100224A ARP110100224A AR079970A1 AR 079970 A1 AR079970 A1 AR 079970A1 AR P110100224 A ARP110100224 A AR P110100224A AR P110100224 A ARP110100224 A AR P110100224A AR 079970 A1 AR079970 A1 AR 079970A1
Authority
AR
Argentina
Prior art keywords
fever virus
yellow fever
cells
viruses
high performance
Prior art date
Application number
ARP110100224A
Other languages
English (en)
Inventor
Patrick M Guertin
Edward Hayman
Cynthia K Lee
Thomas P Monath
Original Assignee
Xcellerex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/043010 external-priority patent/WO2011014416A2/en
Application filed by Xcellerex Inc filed Critical Xcellerex Inc
Publication of AR079970A1 publication Critical patent/AR079970A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una vacuna inactiva y no replicativa que comprende viriones completos, un virus de la fiebre amarilla (FA) inactivado por medios químicos mediante el uso de un método que asegura la preservacion de los epítopes neutralizadores críticos. El virus de la fiebre amarilla ha sido adaptado para propagarlo en células, de modo de obtener mayores rendimientos que los que se obtendrían con virus no adaptados. Métodos para prevenir infecciones del virus de la fiebre amarilla. Reivindicacion 18: Una molécula de ácido nucleico caracterizada porque comprende una secuencia que codifica una proteína de recubrimiento modificada del virus de la fiebre amarilla, donde dicha molécula de ácido nucleico codifica la secuencia de la proteína en SEQ ID N° 4 o 6.
ARP110100224A 2010-07-23 2011-01-24 Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas AR079970A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/043010 WO2011014416A2 (en) 2009-07-31 2010-07-23 High yield yellow fever virus strain with increased propagation in cells

Publications (1)

Publication Number Publication Date
AR079970A1 true AR079970A1 (es) 2012-02-29

Family

ID=45497513

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100224A AR079970A1 (es) 2010-07-23 2011-01-24 Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas

Country Status (6)

Country Link
EP (1) EP2596098B1 (es)
AR (1) AR079970A1 (es)
BR (1) BR112012001553B1 (es)
CA (1) CA2768866C (es)
TR (1) TR201815652T4 (es)
WO (1) WO2012011969A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013306080B2 (en) * 2012-08-24 2019-01-31 Global Life Sciences Solutions Usa Llc Virus purification and formulation process
EP3549603A1 (en) * 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
DE102022114042A1 (de) 2022-06-02 2023-12-07 Gehring Technologies Gmbh + Co. Kg Vorrichtung und Verfahren zum Ausrichten und/oder Maskieren von Steckspulen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
WO2004009764A2 (en) * 2002-07-19 2004-01-29 Board Of Regents, The University Of Texas System Methods and compositions concerning altered yellow fever virus strains
WO2005117958A1 (en) * 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
CA3150417C (en) * 2009-07-31 2023-09-12 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells

Also Published As

Publication number Publication date
CA2768866A1 (en) 2012-01-26
TR201815652T4 (tr) 2018-11-21
CA2768866C (en) 2018-07-24
EP2596098A1 (en) 2013-05-29
WO2012011969A1 (en) 2012-01-26
EP2596098B1 (en) 2018-09-26
EP2596098A4 (en) 2014-01-22
BR112012001553B1 (pt) 2021-12-07
BR112012001553A2 (pt) 2020-07-21

Similar Documents

Publication Publication Date Title
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
UY33667A (es) Compuestos antivirales
CY1121934T1 (el) Αντισωματα anti-fcrn
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
CL2018002825A1 (es) Vacuna contra vrs
BR112013020070A2 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
EA201300915A1 (ru) Новый европейский штамм prrsv
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
AR079970A1 (es) Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CL2011000445A1 (es) Composicion inmunogenica que comprende una o mas cepas del virus del oeste del nilo muerto o inactivado o cualquier antigeno del mismo; metodo para disminuir la incidencia o disminuir la severidad de los sintomas clinicos asociados con o causados por el virus del oeste del nilo en un animal.

Legal Events

Date Code Title Description
FG Grant, registration